Faron Pharmaceuticals Limited (AIM:FARN) shares rallied more than 28% on Monday after disclosing some “truly remarkable” data from the phase I portion of an ongoing cancer study.
Researchers are assessing the potential of bexmarilimab immunotherapy and chemotherapy when used to treat myelodysplastic syndrome (MDS), a blood-borne cancer; specifically in a group that has failed to respond to hypomethylating agents (HMAs).
The latest update showed that four out of the initial five phase I patients were still alive after eight months of follow-up, a survival benefit that stands out compared to current treatments.
Faron’s shares were swapping for 180p as of 12.20pm, compared to the last close at 140p.